Preclinical studies investigating anti‐GPC3 CAR‐T cell therapy in HCC have shown encouraging results, demonstrating the feasibility, safety and potential efficacy of this approach [8, 9]. This evidence concerns the gene GPC3 and hepatocellular carcinoma.